Unraveling a Potential Connection Between Bilirubin Metabolism, Gut Microbiota and Inflammatory Bowel Diseases

Soroka University Medical Center

Status: Unknown

Conditions: Colitis, Ulcerative; Crohn Disease

Study type: Observational

Funder types: Other

Identifiers

NCT03841045

0148-15 SOR

Details and patient eligibility

About

Inflammatory Bowel Diseases (IBDs) are a set of recurrent inflammatory conditions that include the colon and small intestine. The two principal conditions include Crohn's disease (CD) and ulcerative colitis (UC). The etiology of which is likely to stem from the interplay of gut microbial imbalances and host. In this study stool cultures, saliva and skin samples will be taken from all participants.

Full description

Recent studies have shown that certain CD patients harbor microbial communities that are distinct from those of healthy individuals. These studies suggest a central role of the gut microbial population in CD. The high complexity of the gut microbiome, which is the most densely populated bacterial niche, makes the identification of these bacteria a significant challenge. The bacterial population is comprised from 1013 - 1014 individuals, all belonging roughly to a thousand different species, mostly anaerobic, and most of them (roughly 70% - 80%) are uncultivable.

The goals of this project are to examine a potential link between bilirubin metabolism and IBD, by comparing fecal extracts from healthy humans and IBD patients, and to investigate the underlying mechanism explaining these differences.

Enrollment: 150 estimated patients

Sex: All

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• UC
• CD
• healthy Volunteers

Exclusion criteria

• N/A

Trial design

150 participants in 3 patient groups

ulcerative colitis patient

Description:

people that have UC diagnosis can participate in the study. the disease can be at any level and the patients can handle any medications.

CD patient

Description:

people that have CD diagnosis can participate in the study. the disease can be at any label and the patients can handle any medications.

Health people

Description:

control group. no IBD patients can be included. patients with other diseases can be included.